Monday, July 13, 2020, 5:00 PM – 6:00 PM ET
Recent Advances in Medical Oncology: Multiple MyelomaStep-by-step instructions:
Monday, July 13 for the live webinar Faculty
Shaji K Kumar, MD Mark and Judy Mullins Professor of Hematological Malignancies Consultant, Division of Hematology Professor of Medicine Mayo Clinic Rochester, Minnesota Noopur Raje, MD Director, Center for Multiple Myeloma Massachusetts General Hospital Cancer Center Professor of Medicine Harvard Medical School Boston, Massachusetts Moderator Neil Love, MD Research To Practice Miami, Florida Supporters Module 1: Existing Management Paradigm for Multiple Myeloma Module 2: Future Directions in Multiple Myeloma Treatment Target Audience Learning Objectives
CME Credit Form Accreditation Statement Credit Designation Statement American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC) Content Validation and Disclosures FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Kumar — Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies, Amgen Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, GeneCentrix Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Molecular Partners, Oncopeptides, Takeda Oncology; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Carson, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology, TeneoBio; Data and Safety Monitoring Board: Sanofi Genzyme. Dr Raje — Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Novartis, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Lilly.MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc, Tolero Pharmaceuticals and Verastem Inc. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS Supporters |